We measured bone mineral density (BMD) using dual-energy x-ray absorptiometry in 20 patients with Cushing's syndrome (CS) (14 preand 2 postmenopausal women, 4 men) before and in 18 of them also at regular intervals after surgical cure (median duration of follow-up, 36 months). In addition, in the premenopausal women with CS, fast ing blood samples and 2-h fasting urine samples for measurement of biochemical parameters of bone and collagen metabolism were col lected before and in 9 of them also at regular intervals during the first 2 yr after surgery. Marked osteopenia was present in'most patients with active CS (Z-scores: lumbar spine -1.45 ± 1,44 and femoral neck ~ 1.50 ± 1 .02; mean ± sd). No consistent change in BMD was observed at 3 and 6 months after surgery. Thereafter BMD increased consid erably in almost all patients. For the 15 patients with a follow-up of at least 1 yr, Z-scores at the last evaluation were -0.65 ± 1.27 for the lumbar spine and -0.98 ± 1.02 for the femoral neck (both/5 < 0.002 compared with pretreatment values). In the premenopausal patients, the increase in BMD both in the lumbar spine and in the femoral neck at 24 months was inversely correlated with age (r = -0.733, P < 0.03, and r ~ -0.667, P < 0.05, respectively). Serum levels of osteocalcin, bone alkaline phosphatase, carboxyterminal propeptide of type I pro
collagen, aminoterminal propeptide of type III procollagen, and the cross-linked telopeptide of type I collagen were not significantly dif ferent between the group of 14 premenopausal patients with active CS and a control group of 18 age-matched healthy premenopausal women. However, the urinary hydroxyproline/creatinine ratio was significantly higher in patients with CS (24.6 ± 9.6 vs. 1.6.2 ± 3.5 /xmol/mmol, P < 0.01). In all 9 premenopausal patients, serum levels of osteocalcin increased considerably between 0 and 3 months (from 1.04 ± 0.20 to 3.82 ± 0.30 nmol/L) (mean ± SEM, P < 0.0001), indi cating a prompt increase of osteoblast activity. Also serum levels of carboxyterminal propeptide of type I procollagen, aminoterminal propeptide of type III procollagen, and cross-linked telopeptide of type I collagen, and the urinary hydroxyproline/creatinine ratio increased significantly between 0 and 3 months. Thereafter these levels de creased gradually, We conclude that marked osteopenia in the lumbar spine and femoral neck is present in most patients with active Cush ing's syndrome, Bone density does not consistently change in the first 6 months after cure, despite an apparently rapid restoration of os teoblast activity. Thereafter remarkable improvement of bone density can be observed in almost all patients. (J Clin Endocrinol Metab 80: [2859] [2860] [2861] [2862] [2863] [2864] [2865] 1995) bl« A«*!"1 I N HIS CLASSIC report on endogenous glucocorticoid ex cess attributable to ACTH-producing pituitary tumors, Harvey Cushing recognized osteoporosis as a serious con sequence of hypercorticism (1 ) . This type of bone loss is more m arked in trabecular than in cortical bone and frequently leads to fractures of vertebrae, ribs, and pubic bones (2) .
In recent years, accurate methods to assess bone mineral density (BMD) have become available, making it possible to study the reversibility of osteopenia after cure of Cushing's syndrome. However, only a small number of longitudinal observations on BMD in patients with treated Cushing's syndrom e have been reported so far (3, 4) . Pocock et aL (3) described two patients in whom lumbar and femoral BMD increased postopera lively. Unfortunately, in these patients no information on BMD before surgery was available. Lufkin L 'f nl, (4) followed nine patients for 3-66 months after surgery and observed a 20% increase in lumbar BMD. However, most subjects had only a single follow-up measurement, and BMD in the proximal femur was not assessed.
In the present study BMD is evaluated in 20 patients w ith active Cushing's syndrome. In 18 of these patients BMD w as also measured at regular intervals after surgical cure. D u ration of follow-up in these patients ranged from 3-60 months. Fifteen patients were followed for at least 12 m onths after successful surgery. In addition, data are presented on serum levels of markers of osteoblastic activity and collagen synthesis and on serum and urine markers of bone resorption before and during the first 2 yr after surgical cure of Cushing's syndrome. Methods BMD measurements. BMD was measured two times before (on 2 con secutive days) and at 3,6,12,18,24,36,48, and 60 m onths after definitive surgical treatment BMD was measured in the lum bar spine (LI-14; anterior-posterior) and the left femoral neck using dual-energy x-ray absorptiometry (Hologic Inc., Waltham MA, m odel QDR-1000). The coefficient of variation (CV) for repeat measurements in our hospital is 1,0% in the lumbar spine and 1,7% in the femoral neck (5). In none of the patients w ere fractures of lumbar vertebrae seen on radiographs m ade before and 24 months after surgery.
P atien ts and M ethods

BMD measurements are expressed in g /c m 2. Furthermore, for each BMD measurement a Z-score w as calculated according to the formula Z-score (sd ) = [patient's value (g /c m 2) -mean of a reference group of age-and sex-matched healthy individuals (g /c m 2)] hs d reference group (g /c m 2).
Results of BMD measurements before and during the first 2 yr after surgical treatment in patients 1 ,2 ,3 ,6, and 15 have been reported earlier (6) .
Biochemical measurements. Before surgical therapy in the 14 premeno pausal w om en with Cushing's syndrome, blood samples were drawn (between 0830 and 0930 h) and 2-h urine sam ples were collected (be tween 0800 and 1000 h) after an overnight fast for measurement of biochemical parameters of bone and collagen metabolism. In 9 of these premenopausal patients (1-9), the parameters (except for bone alkaline phosphatase) were also determined at3, 6, 12, 18, and 24 months after definitive surgical treatment. Data were compared with those of a group of 18 age-matched healthy premenopausal w om en in the early follicular phase of the menstrual cycle.
Blood sam ples for measurement of serum bone alkaline phosphatase, osteocalcin, carboxyterminal propeptide of type I procollagen (PiCP), amino terminal propeptide of type III procollagen (PIIINP) and the crosslinked telopeptide of type I collagen (ICTP) were centrifuged immedi ately after collection. Thereafter, samples were kept at -20 C until analyzed. A ll sam ples w ere run in duplicate. Serum bone alkaline phos phatase was assayed by a direct immunoradiometric assay (Ostase, Hybritech, San D iego CA) using two monoclonal antibodies directed against the bone isoenzym e and with bone alkaline phosphatase purified from hum an osteosarcoma cells as a standard. Intra-and interassay CVs
were 5% and 7.5%, respectively. Serum osteocalcin was measured by RIA (OSTK-PR, CIS, Gif-sur-Yvette Cedex, France; intraassay CV 6% , interassay CV 7%). Serum PICP was measured by RIA (PICP RIA-ktt, Orion Diagnostica, Espoo, Finland). Intra-and interassay CVs using a reference serum sample were 3% and 5%, respectively. Serum PIIiNP was determined by RIA (PIIINP RIA-kit, Orion Diagnostica). Intra-and interassay CVs using a reference serum sample were 4% and 6%, re spectively. Serum ICTP was measured by RIA (ICTP RIA-kit, Orton Diagnostica; intraassay CV 4.5%, interassay CV 6%).
Urines w ere not acidified before analysis. Urinary creatinine was measured on a Cobas Bio automatic analyzer system (Roche, Basel, Switzerland). Urinary hydroxyproline w as measured with the H ypronosticon kit (Organon Teknika, Boxtel, The Netherlands).
Statistical analyses
Statistical analyses were performed using the Wilcoxon signed rank test for paired observations (P values denoted as P), the Mann-Whitney U test for unpaired observations (P = P*) and the Spearman rank cor relation test (P = P**). Unless otherwise stated, the mean values ± 1 sd are given.
correlation between BMD (Z-scores) at either site and age, duration of symptomatic glucocorticoid excess, duration of amenorrhea, or mean 24-h plasma cortisol in the group of premenopausal patients.
Results
BMD in patients with active Cushing's syndrome
M arked osteopenia was present in most patients with ac tive Cushing's syndrom e ( Table 2 ). The decrease in BMD was equally severe in the lumbar spine and femoral neck (Zscores: lum bar spine -1.45 ± 1.44 and femoral neck -1.50 ± 1.02; P > 0.10). In 15 of 20 patients, BMD at one or both sites was lower than -1 s d and in about half of the patients even lower than -2 s d below the mean value when compared with the reference groups of age-and sex-matched healthy indi viduals. There was no significant difference in BMD between patients with pituitary-dependent Cushing's syndrome (Zscores: lum bar spine -1.56 ± 1.32 and femoral neck -1.76 ± 0.85) and those with an adrenal adenoma (Z-scores: lumbar spine -1.19 ± 1.80 and femoral neck -1.39 ± 1.09).
In the group of 14 premenopausal women, BMD (Z-score) in the lum bar spine was significantly correlated with BMD in the femoral neck (r = 0.553, P** <0.05). BMD in the lumbar spine was also significantly correlated with the body mass index (k g /m 2) (r = 0.644, P** < 0.02) in the group of pre m enopausal women, whereas there was no significant cor relation between BMD in the femoral neck and body mass index (r = 0.355, P** > 0.10). There was also no significant
BMD after surgical cure of Cushing's syndrome
After surgery no consistent change in BMD was observed at 3 and 6 months ( Fig. 1 ). In fact, BMD was lowered by 2% or more in comparison with pretreatm ent values at one or both time points in 6 of 17 patients at the lum bar spine an d in 11 of 16 patients at the femoral neck. In the group of premenopausal women, there was a highly significant in verse correlation between age and increase in BMD in the lumbar spine in the first 6 months after surgery (r = -0.925, P** < 0.0005).
From 6 months onward BMD increased considerably in most patients ( Fig. 1 ). For the 15 patients w ith a duration of follow-up of at least 1 yr, Z-scores at the time of the last evaluation are given in Table 2 . At the last evaluation Zscores in these 15 patients were -0.65 ± 1.27 for the lum bar spine and -0.98 ± 1.02 for the femoral neck (both P < 0.002 compared with pretreatment values). W hen com pared w ith pre treatment values, BMD at the last m easurem ent had in creased ill the lumbar spine in 12 of 15 patients (in 7 of them by more than 15%; increase 22.1% ± 4.8%, n = 7) and in the femoral neck in 11 of 15 patients (in 5 of them by m ore than 15%; increase 22.0% ± 4.0%, n = 5). However, at the last measurement, BMD in the lum bar spine was still low er than crease in BMD in the lumbar spine at 24 m onths was in versely correlated with age (r = -0.733, P** < 0.03) and positively correlated with the increase in BMD in the femoral neck at 24 m onths (r = 0.767, P** < 0.03) and w ith the increase in BMD in the lumbar spine at 6 months (r = 0,867, P** < 0.005). The increase in BMD in the femoral neck at 24 months was also inversely correlated with age (r 0 .0 5 ).
0.667, P** < Biochemical parameters of bone and collagen metabolism in premenopausal patients with active Cushing's syndrome
Serum levels of parameters of osteoblast activity and col lagen synthesis (osteocalcin; bone alkaline phosphatase, PICP, PIIINP) w ere not significantly different between the group of 14 prem enopausal patients with active Cushing's syndrome and the group of 18 age-matched healthy pre menopausal w om en (Table 3 ). Of the parameters of bone resorption, the urinary hydroxyproline/creatinine ratio was significantly higher in patients with Cushing's syndrome, whereas serum levels of ICTP were not different between both groups.
In the patients with Cushing's syndrome, serum osteocal cin levels were significantly correlated with those of PICP (r -0.645, P** < 0.03) and those of bone alkaline phosphatase (r = 0.639, P** < 0.05). N o other significant correlations were observed between the above-mentioned biochemical param eters in the group of premenopausal patients with Cushing's syndrome. Z-scores in the lum bar spine or the femoral neck did not correlate significantly with any of the biochemical parameters of bone and collagen metabolism.
In the group of healthy premenopausal women, serum osteocalcin levels were significantly correlated with those of PICP (r = 0.602, P** < 0.01) and of bone alkaline phosphatase (r = 0.783, P** < 0.0001), as they were in the patients with Cushing's syndrome. In the healthy women, serum PICP levels were also correlated w ith serum levels of bone alkaline phosphatase (r = 0.737, P** < 0.0003). Unlike the serum levels of ICTP in the patients with Cushing's syndrome, serum levels of ICTP in the healthy premenopausal women were significantly correlated with those of osteocalcin (r = 0.504, P** < 0.05), PICP (r = 0.608, P** < 0.01), and bone alkaline phosphatase (r = 0.740, P** < 0.0003).
Biochemical parameters of bone and collagen metabolism after surgical cure of premenopausal patients with Cushing's syndrome
In nine prem enopausal patients with Cushing's syndrom e we determined the above-mentioned parameters, except for bone alkaline phosphatase, at regular intervals during the first 2 yr after surgical cure (Fig. 2) . In all patients, serum levels of osteocalcin increased considerably between 0 and 3 months [from 1.04 ± 0.20 to 3.82 ± 0.30 nm ol/L (mean ± s e m ), P < 0.0001], indicating a prom pt increase of osteoblast activity. Also serum levels of PICP and PIIINP increased significantly between 0 and 3 months [PICP from 173 ± 32 to 250 ± 35 /¿g/L (mean ± s e m ), P < 0.05, and PIIINP from 3.14 ± 0.89 to 14.80 ± 1.75 /xg/L (mean ± s e m ), P < 0.0001]. Thereafter PICP levels decreased gradually (24 m onths vs, 3 months, P < 0.05; 24 months vs, healthy controls, P* > 0.10). Serum osteocalcin and PIIINP levels also decreased gradu ally from 3 months after surgery onward (24 months vs. 3 months, both P < 0.05), but at 24 months after surgery these levels were still elevated when compared with levels in healthy women (P* < 0.04 for PIIINP and P* < 0.006 for osteocalcin). Of the parameters of bone resorption, the uri nary hydroxyproline/creatinine ratio and serum levels of ICTP increased in all patients betw een 0 and 3 m onths [ICTP; from 4.07 ± 0.65 to 14.09 ± 2.30 jug/L (mean ± s e m ), P < 0.05; urinary h y d ro x y p ro lin e/creatin in e ratio: from 27.36 ± 2.85 to 70.73 ± 7.45 /xmo l/m m o l (mean ± s e m ), P < 0.0001]. Thereafter the u rin a ry hydroxyproline/creatinine ratio de creased gradually (24 m onths vs. 3 months, P < 0.005; 24 m onths vs. healthy controls, P* > 0.10). Serum ICTP levels also decreased g rad u ally from 3 m onths after surgery on w ard (24 m onths vs. 3 m onths, P < 0.05), but at 24 m onths after surgery these levels w ere still elevated w hen com pared with levels in healthy w o m en (P* < 0.05).
D iscu ssio n
In the present stu d y , m ark ed osteopenia, equally severe in the lum bar spine and in the fem oral neck, was dem onstrated by dual-energy x-ray absorptiom etry in m ost patients w ith active Cushing's sy n d ro m e. In a prelim inary report, Mercado-Asis et al. (7) , u sin g the sam e technique as that used in our study, em phasized that the decrease in BMD was m ore severe in pediatric th a n in adult patients w ith C ushing's syndrome [in ag reem en t w ith the observation that young patients receiving glucocorticoid therapy lose bone m ore rapidly than do older patien ts (8) ]. In our group of 14 ad u lt prem enopausal patients w ith Cushing's syndrom e, we could not dem onstrate a significant correlation betw een BMD and age, nor between BMD a n d estim ated duration of sym ptom atic glucocorticoid excess, duration of amenorrhea, and mean 24-h plasma cortisol. Interestingly, a significant posi tive correlation between BMD in the lumbar spine and body mass index w as observed. Apparently a high body mass protects against glucocorticoid-induced bone loss in the lum bar spine. The mechanism of the profound decrease of BMD in C ush ing's syndrome cannot be derived from our study. It is, however, most likely that several factors act together, e.g. the detrimental effect of hypercortisolism on bone formation, the glucocorticoid-induced decrease of muscular strength lead ing to impaired physical activity, and the glucocorticoidinduced impairment of the activity of the pituitary-gonadal axis and of growth hormone secretion.
Histomorphometric studies in patients treated w ith glu cocorticoids show a marked decrease in the thickness of osteoid seams, a low mineral apposition rate as measured by tetracy cline labeling, and a reduced mean wall thickness (9, 10) . These findings support the view that glucocorticoid administration decreases bone formation because of direct or indirect inhibi tion of osteoblast function. Histomorphometric studies in a few patients with Cushing's syndrome revealed a similar pattern (3, 9) . In our group of 14 premenopausal patients with active Cush ing's syndrome, we found normal serum levels of markers of osteoblast activity and collagen synthesis. In our opinion the normal serum levels of osteocalcin, bone alkaline phosphatase, and PICP indicate either that osteoblast activity w ould be nor mal in these premenopausal Cushing's patients or that these biochemical parameters lack sufficient sensitivity to detect small decreases of osteoblast activity in patients with Cushing's syndrome at the time of diagnosis. In this respect it has to be noted that the mean duration of estimated symptomatic cortisol excess in our patients was more than 2.5 yr and that in corti costeroid-treated patients bone loss seems to be m ost marked during the first 6 -12 months of treatment, w ith the rate of bone loss sharply slowing down or even approaching zero thereafter (1 1 ,12) . Our data on markers of osteoblast activity are in agree ment with those from Ebeling et al (13) w ho found normal serum levels of bone alkaline phosphatase and PICP in a group of 25 patients with exogenous (n = 10) or endogenous (n = 15) glucocorticoid excess. Normal serum levels of PICP in patients with Cushing's syndrome were also reported by Piovesan etal (14) . In contrast to our data, decreased serum levels of osteo calcin in Cushing's syndrome were reported in a number of studies (3, (13) (14) (15) (16) .
Histomorphometric studies, which show an increase in trabecular resorption surfaces, and calcium kinetic studies suggest that bone resorption is enhanced by glucocorticoids (9, 17, 18) . This increased bone resorption is possibly attrib utable to secondary hyperparathyroidism, which is m edi ated by the negative calcium balance resulting from the in hibitory effect of steroids on both intestinal calcium absorption and renal conservation of calcium. In our study two supposed indicators of bone resorption w ere m easured. We found that the urinary hydroxyproline/creatinine ratio was significantly higher in premenopausal patients w ith Cushing's syndrome than in healthy prem enopausal women, whereas serum levels of ICTP w ere not different in both groups. However, it has to be emphasized that the first parameter is not specific for bone resorption because part of the hydroxyproline in urine could have been derived from soft tissue turnover and repair, whereas the sensitivity and specificity of the latter param eter in detecting changes in bone resorption is not yet established. Interestingly, param eters of bone formation (bone alkaline phosphatase, osteo calcin, and PICP) and those of bone resorption (ICTP) are positively correlated in healthy prem enopausal women but not in our premenopausal Cushing's patients, suggesting uncoupling of bone form ation and resorption in the latter.
In the first 6 months after surgery there was a highly significant inverse correlation between age and increase in BMD in the lumbar spine, A t 24 months after surgery, such a significant inverse correlation between age and the increase in BMD was present for both the lum bar spine and the femoral neck. Apparently, in older prem enopausal women the im provem ent of osteopenia after cure of Cushing's syn drome is less than that in younger women, at least during the first 2 yr after surgery.
It is of interest that in the first 6 months after surgery BMD was lowered by 2 % or more in comparison with pretreatment values in 6 of 17 patients in the lum bar spine and in 11 of 16 patients in the femoral neck. In the group of premenopausal women, serum levels of osteocalcin increased considerably to above the normal range in all patients; these levels re mained elevated during the whole period of observation, indicating a prom pt and sustained increase of osteoblast activity. In parallel w ith the increase in osteocalcin levels, serum levels of PICP and PIIINP increased significantly after treatment, but their increase w as not sustained. Both param eters of bone resorption (serum ICTP and urinary hy droxyproline/creatinine ratio) also increased significantly after surgery and only gradually normalized in the years thereafter. We interpret these findings as an expression of restoration of the coupling betw een osteoblast and osteoclast function after cure of Cushing's syndrome. It m ay be that in such a situation mineralization of newly formed osteoid is delayed, thus explaining the decrease in BMD occurring in a considerable num ber of patients after cure of Cushing's syndrome. However, interpretation of the pattern of the uri nary hydroxyproline/creatinine ratio and the serum level of ICTP has to be cautious in light of the limitations of both param eters in detecting bone resorption, especially during nonsteady-state conditions. Furthermore, the increase in both param eters after treatm ent of Cushing's syndrom e might be caused by an increase of soft tissue turnover and repair and not by an increase in bone resorption. Unfortu nately, histomorphometric studies in series of patients with Cushing's syndrome after treatm ent are lacking.
In a cross-sectional study, M anning et al (19) found that BMD in the himbar spine and femoral neck in 17 patients cured earlier of Cushing's syndrom e (8.6 ± 1.6 yr; mean ± s e m ) w as normal. These authors adduced that the regaining of bone density is gradual, probably taking approxim ately 10 yr to become complete. In our study (with a m uch shorter follow-up), BMD at the time of the last m easurem ent was still lower than -1 s d in 6 of 15 patients in the lum bar spine and in 7 of 15 patients in the femoral neck. Additional follow-up of our patients will determ ine whether BMD will recover completely.
We conclude that m arked osteopenia in the lum bar spine and femoral neck is present in most patients w ith active Cushing's syndrome. Bone density does not consistently change in the first 6 months after cure, despite an apparently rapid restoration of osteoblast activity. Thereafter remark able improvement of bone density can be observed in almost all patients.
